Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 27, 2022

Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL and SLL

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
J. Clin. Oncol 2022 Nov 17;[EPub Ahead of Print], P Hillmen, B Eichhorst, JR Brown, N Lamanna, SM O'Brien, CS Tam, L Qiu, M Kazmierczak, K Zhou, M Šimkovič, J Mayer, A Gillespie-Twardy, M Shadman, A Ferrajoli, PS Ganly, R Weinkove, S Grosicki, A Mital, T Robak, A Österborg, HA Yimer, T Salmi, M Ji, J Yecies, A Idoine, K Wu, J Huang, W Jurczak

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading